28/04/2023
Scientists may have found a potential solution to treat respiratory syncytial virus (RSV), a severe respiratory infection that primarily affects infants and elderly people. The virus was discovered in 1957 and is highly contagious to people of all ages, with an estimated 33 million children less than five years of age being infected with RSV every year. Though there are no antiviral drugs designed specifically for RSV, researchers have developed vaccines and monoclonal antibodies that have shown promise in preventing severe illness caused by RSV. Some of these vaccines and antibodies are currently under testing or awaiting approval by regulatory authorities. While the virus remains a major concern, precautions such as social isolation and mask use have led to the eradication of RSV during the COVID-19 pandemic. However, the virus has reemerged in the summer of 2021, and the efficacy of vaccines and therapies under development in the autumn may help reduce hospitalizations and fatalities caused by RSV.
Our current understanding of RSV vaccinations and antibodies is as follows:
Scientists may have found a potential solution to treat respiratory syncytial virus (RSV), a severe respiratory infection that primarily affects infants and elderly people. The virus was discovered in 1957 and is highly contagious to people of all ages,